RenovoRx, Inc is a clinical-stage biopharmaceutical company based in Los Altos, CA, specializing in the development of innovative combination therapies for the targeted treatment of difficult-to-access cancers. Their proprietary therapy platform, Trans-Arterial Micro-Perfusion (TAMP), delivers precise therapeutic delivery directly to the tumor, potentially minimizing toxicities associated with systemic intravenous therapy. RenovoRx's lead product candidate, RenovoGem, is currently being evaluated in a Phase III clinical trial for the treatment of locally advanced pancreatic cancer, with other potential indications in the pipeline.
With a commitment to improving therapeutic outcomes and quality of life for cancer patients, RenovoRx aims to develop transformative therapies that address high unmet medical needs. Their approach offers the potential for increased safety, tolerance, and improved efficacy in cancer treatment. RenovoRx has received FDA Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing market exclusivity upon approval.
Generated from the website